Risperidone augmentation of SRI treatment for refractory obsessive- compulsive disorder

Journal of Clinical Psychiatry

Volumn 57, Issue 7, 1996, Pages 303-306

  Saxena, Sanjaya ^a,e   Wang, Dora ^c   Bystritsky, Alexander ^a   Baxter Jr , Lewis R ^a,b,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIPRAMINE; CLOZAPINE; CLOZAPINE DERIVATIVE; FLUOXETINE; FLUPHENAZINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; PAROXETINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; VALPROIC ACID;

ADULT; AKATHISIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; IMAGERY; MALE; MORBIDITY; OBSESSION; PRIORITY JOURNAL; PSYCHOSIS; RATING SCALE; TREATMENT FAILURE;

ADULT; AKATHISIA, DRUG-INDUCED; COMORBIDITY; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 0029896442     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Goodman WK, Price LH, Rasmussen SA, et al. Efficacy of fluvoxamine in obsessive-compulsive disorder: a double-blind comparison with placebo. Arch Gen Psychiatry 1989;46:36-43
2. McDougle CJ, Goodman WK, Price LH, et al. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: a double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 1995;51:302-308
3. Hwang MY, Martin AM, Lindenmayer JP, et al. Treatment of schizophrenia with obsessive-compulsive features with serotonin reuptake inhibitors [letter]. Am J Psychiatry 1993;150:1127
4. Stroebel CF, Szarek BL. Use of clomipramine in treatment of obsessive-compulsive symptomatology. J Clin Psychopharmacol 1984;4:98-100
5. Kindler S, Kaplan Z, Zohar J. Obsessive-compulsive symptoms in schizophrenia. In: Hollander E, ed. Obsessive-Compulsive Related Disorders. Washington, DC: American Psychiatric Press; 1993:203-214
6. Jenike MA, Baer L, Minichiello WE, et al. Concomitant obsessive-compulsive disorder and schizotypal personality disorder. Am J Psychiatry 1986;143:530-532
7. McDougle CJ, Goodman WK, Price LH, et al. Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry 1990;147:645-648
8. Patil VJ. Development of transient obsessive-compulsive symptoms during the treatment with clozapine [letter]. Am J Psychiatry 1992; 149:272
9. Baker RW, Chengappa KNR, Baird JW, et al. Emergence of obsessive compulsive symptoms during treatment with clozapine. J Clin Psychiatry 1992;53:439-442
10. Young CR, Bostic JQ, McDanald CL. Clozapine and refractory obsessive-compulsive disorder: a case report [letter]. J Clin Psychopharmacol 1994; 14:209-210
11. Patel B, Tandon R. Development of obsessive-compulsive symptoms during clozapine treatment [letter]. Am J Psychiatry 1993;150:836
12. Remington G, Adams M. Risperidone and obsessive-compulsive symptoms [letter]. J Clin Psychopharmacol 1994;14:358-359
13. Kopala L, Honer WG. Risperidone, serotonergic mechanisms, and obsessive-compulsive symptoms in schizophrenia [letter]. Am J Psychiatry 1994;151:1714-1715
14. McDougle CJ, Fleischmann RL, Epperson CN, et al. Risperidone addition in fluvoxamine-retractory obsessive-compulsive disorder: three cases. J Clin Psychiatry 1995;56:526-528
15. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale, I: development, use, and reliability. Arch Gen Psychiatry 1989;46:1006-1011
16. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40
17. Crewe HK, Leonard MS, Tucker GT, et al. The effect of serotonin reuptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992;34:262-265
18. Heykants J, Huang M-L, Mannens G, et al. The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry 1994;55(5, suppl): 13-17
19. Richelson E. Preclinical pharmacology of antipsychotic drugs: relationship to efficacy and side effects. J Clin Psychiatry Monograph 1994;12(2): 17-23
20. Leysen JE. 5-HT2 receptors: location, pharmacological, pathological, and physiological role. In: Langer SZ, Brunello N, Racagni G, et al, eds. Serotonin receptors: pharmacologic significance and clinical implication. Basel, Switzerland: Karger; 1992:31-43